FDA·Medicines·May 13, 2026

Acella recalls naproxen oral suspension over lead and lithium contamination

The recalled naproxen liquid, a prescription medicine sold in 16 fl oz (473 mL) bottles, contains lead and lithium above the allowed limits, and the notice covers 6,336 bottles sold nationwide.

What to do

The notice does not give instructions. Read the official notice for details.

Note from Recalled Today: Don't stop taking a prescribed medicine before you talk to your pharmacist or doctor.

Recall details

Product
NAPROXEN ORAL SUSPENSION, USP, 125 mg/5mL, Rx only, 16fl oz (473 mL) bottles, Distributed by: Acella Pharmaceuticals, LLC, Alpharetta, GA 30005, Made in Canada NDC 42192-619-16
Hazard
Chemical contamination; presence of lead and lithium above specification
Units
6,336 bottles
Where sold
Nationwide
FDA classification
Class II · Ongoing
Classified by FDA
May 6, 2026
Recall started
April 20, 2026
FDA enforcement report
May 13, 2026
Identifiers
  • Codes: Lot: 23F02, Expires: 05/2026; 25A37, Expires: 01/2028.
  • FDA recall number: D-0523-2026

The headline, summary and steps above are written in plain English from the official notice below. Identifiers are copied exactly as the agency published them. Always check the official notice before you act.

Official notice

The notice's own wording from FDA.

Product
NAPROXEN ORAL SUSPENSION, USP, 125 mg/5mL, Rx only, 16fl oz (473 mL) bottles, Distributed by: Acella Pharmaceuticals, LLC, Alpharetta, GA 30005, Made in Canada NDC 42192-619-16
Reason for recall
Chemical contamination; presence of lead and lithium above specification
Classification
Class II (Ongoing)
Distribution
Nationwide
Quantity
6,336 bottles

Related recalls